



Switzerland - Taiwan Biotech Seminar

-The 2nd Switzerland - Taiwan Joint Business Council Meeting

The **Swiss-Asian Chamber of Commerce**, in cooperation with **Chinese International Economic Cooperation Association (CIECA)** and the **Taiwan Bio Industry Organization** and the **Swiss Biotech Association** is pleased to invite you to a presentation to get firsthand information on the Taiwan Biotechnology market.

Date: **Thursday, 2 November 2017**

Time: 10:15hrs to 14:30hrs

Venue: Zunfthaus zur Meisen, Münsterhof 20 CH-8001 Zurich

Taiwan is undergoing a boom in biotechnology, rewarding years of dedicated effort from its stakeholders. More and more locally-developed drugs are entering late-stage clinical trials, and new companies, service providers, and manufacturing facilities are emerging to fill rapidly growing industry needs.

Overseas interest is picking up as well, with licensing, partnering and investment agreements at an all-time high. The biotech industry in Taiwan has a set of unique characteristics and strengths that make it an appealing prospect to the global life science community looking for a partnership, investment or licensing opportunities.

These include:

1. Vibrant VC industry and capital markets
2. Strong business and cultural ties to the Greater China market
3. World-class clinical trial capability
4. Transparent legal and business environment, with strong IP protection
5. Well established private-public partnerships with deep innovation pipelines
6. Highly-educated, motivated and cost-effective workforce
7. Executives with overseas training, global view, and Big Pharma experience
8. Strong government support, subsidies, and tax breaks

As healthcare is moving from a “one size fits all” model towards a more personalized approach, bringing together Taiwan’s newest diagnostic tools with precision therapeutics, existing strengths in ICT and device industries means that Taiwan is well placed to excel in this evolving healthcare ecosystem.

Taiwan’s biotech industry market value has reached 900bil TWD (30bil USD) and will soon approach its first trillion TWD as Taiwan becomes an integral part of the global biopharma industry chain. The government’s initiatives to support Taiwan’s biotech development and innovation are critical for continued strong growth momentum.

We welcome you to this most interesting seminar that will bring investors and possible partners on biotechnology together. We look forward to personally welcoming you at Zunfthaus zur Meisen in Zurich.

Early registration is highly recommended.

Program, Thursday, 2 November 2017

| | |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10:00 – 10:45 | Registration |
| 10:45 – 10:50 | Opening Remarks By Mr. Alexander Hagemann , Vice President, Chairman Taiwan Committee, Swiss-Asian Chamber of Commerce |
| 10:50 – 10:55 | Opening Remarks By Mr. Johnsee Lee , Chairman, Taiwan Bio Industry Organization |
| 10:55 – 11:00 | Special Remarks By Dr. Klement Ruey-Sheng Gu , Representative, Taipei Delegation of Culture and Economy |
| 11:00 – 11:15 | Keynote Speech By Mrs. Cathy Kroll , CEO, Swiss Biotech Association Subject: Overview on Swiss Biotech |
| 11:15 – 11:30 | Keynote Speech By Dr. Apo Huang , Secretary General, Taiwan Bio Industry Organization Subject: Biotech in Taiwan |
| 11:30 – 11:45 | Short Pitches - Swiss Company By Mrs. Maria Bobadilla , MD, Ph.D., Senior Director, Roche Partnering Innovation, F. Hoffmann-La Roche Ltd. Subject: Partnering at Roche |
| 11:45 – 12:00 | Short Pitches - Taiwanese Company |
| 12:00 – 12:15 | Q & A Session |
| 12:15 – 13:30 | Lunch and Networking |
| 13:30 – 15:00 | Informal Business Matching 1:1 meetings, informal or prearranged |



Registration Form

Registration: Please register by returning the form below to the Swiss-Asian Chamber of Commerce, P.O. Box 1073, 8032 Zurich, faxing 041/620 88 03 or emailing sacc@sacc.ch, by **Monday, 23 October 2017 at the latest**. The cost of the event, which includes apéro and lunch is CHF 140.00 for SACC/SBA-Members and CHF 170.00 for Non-Members. You will receive a confirmation including the invoice after your registration. Cancellations will be accepted until **Friday, 27 October 2017, 10.00 a.m.:** - otherwise a full no-show charge applies.

Last Name: First Name:
Position: Company:
Full Address:
Phone: Fax: E-mail:
Date: Signature:
Registration for a B2B with company

Cooperation Partners



Taiwan Economy and Biotech Industry ranked high globally

- Investment Risk #3 (BERI)
- Entrepreneurship #7, #1 Asia (GEDI)
- Global Competitiveness #13 (IMD)
- Higher Education #12 (WEF)
- Innovation Capability #10 (WEF)
- Knowledge-Based Economy #13, #1 Asia (World Bank)